Your session is about to expire
← Back to Search
Pembrolizumab for High-Grade Meningioma
Study Summary
This trial is studying pembrolizumab to see how well it works in treating patients with high grade meningioma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have received treatment before.My meningioma has grown after I completed radiation therapy.I can do most of my daily activities without help.I have not taken drugs that weaken my immune system in the last 3 months.My meningioma has come back or spread beyond its original location.I have a lesion in my brainstem.You have a measurable main lesion that is at least 10 millimeters in size and can be clearly seen on MRI or CT scans.I have had multiple treatments for my condition.I've been on a stable dose of dexamethasone (2mg or less) for the last week.I have stable brain tumors for 6 months due to NF.My cancer has grown by 25% or more in less than 2 years.I have a growing meningioma after radiation, and it's been 24 weeks or my tumor is growing outside the treated area.I have a tumor that can be clearly seen and measured on an MRI or CT scan.I may or may not have had previous medical treatments.My meningioma was caused by previous radiation treatments.I haven't had cancer treatment or recovered from its side effects in the last 2 weeks.I have been diagnosed with an immunodeficiency.I have an autoimmune disease treated with medication in the last 2 years.I have a history of lung inflammation not caused by an infection.I am currently being treated for an infection.I have been diagnosed with HIV.I have an active Hepatitis B or C infection.I have not received a live vaccine in the last 30 days.I have a Grade II or III meningioma with measurable disease after surgery.I may or may not have had previous medical treatments.I agree to use contraception during the study.I need to take more than 2mg/day of dexamethasone before starting therapy.I have an active tuberculosis infection.I do not have any unmanaged ongoing illnesses.I have another cancer that is getting worse or needs treatment.My meningioma has come back or spread beyond its original location.You are allergic to pembrolizumab or any of its ingredients.I have had multiple treatments for my condition.You cannot have a brain MRI scan.I have been treated with drugs targeting PD-1, PD-L1, or PD-L2.My meningioma has spread beyond the brain.You have a diagnosed mental health condition or issues with substance abuse.My recent tests show my organs and bone marrow are functioning well.My MRI shows a tumor in my brain that's at least 10mm big after surgery.Your main tumor has gotten at least 25% bigger on imaging.I am 18 years old or older.
- Group 1: Pembrolizumab
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals have been accepted into the experiment thus far?
"Unfortuantely, the aforementioned trial has closed its enrollment window; it was initially posted on November 7th 2017 and last updated July 29 2021. However, there are currently 46 medical studies recruiting patients with high grade meningioma and 961 trials for Pembrolizumab in progress."
What risk factors should be taken into account when utilizing Pembrolizumab?
"Pembrolizumab's safety rating is 2, as it has been trialled in Phase 2 but efficacy data is still lacking."
For what maladies can Pembrolizumab be prescribed?
"Pembrolizumab is regularly prescribed to those with malignant neoplasms, yet it can also assist patients dealing with advanced melanoma, microsatellite instability high tumours, and chemo-resistance."
Are there any vacancies remaining for this investigation?
"Clinicaltrials.gov stipulates that this clinical trial is not enrolling any further patients at this time, which was last updated on July 29th 2021 and originally posted November 7th 2017. Nevertheless, there are over one thousand other medical trials currently in need of participants."
Is there prior research on Pembrolizumab that can inform our current understanding?
"Currently, there are 961 active studies involving pembrolizumab; 122 of which have reached the third phase. Houston has several locations running this trial, but overall 35727 medical centres worldwide have started trials utilizing pembrolizumab."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger